Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Recombinant Human Anti-PD-1 Monoclonal Antibody for Patients With Advanced Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03713905
Recruitment Status : Recruiting
First Posted : October 22, 2018
Last Update Posted : October 23, 2018
Sponsor:
Information provided by (Responsible Party):
Guangzhou Gloria Biosciences Co., Ltd.

Brief Summary:

To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer).

To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) and efficacy.


Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: GLS-010 Phase 1

Detailed Description:
Dose escalation study: Primary purpose: To investigate the safety and tolerability of GLS-010 in subjects with advanced solid tumors (mainly gastric cancer, esophageal cancer). Secondary purpose: 1. To characterize the pharmacokinetics(PK) profile of GLS-010; 2. To determine dose-limiting toxicity(DLT), maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) for GLS-010; 3. To assess the preliminary anti tumor activity of GLS-010; 4. To assess programmed cell death-1 (PD-1) receptor occupancy. Exploratory purpose: 1. To investigate the preliminary relationship between the expression of the ligand of PD-1 (PD-L1) /PD-L2 and efficacy; 2. To characterize immunogenicity of GLS-010. Expansion study: Primary purpose: To assess the preliminary anti-tumor activity of GLS-010 in subjects with advanced solid tumors(gastric cancer, esophageal cancer); Secondary purpose: 1. To further assess the safety and tolerability of GLS-010; 2. To further assess the safety and tolerability of GLS-010 in subjects with advanced tumors. Exploratory purpose: 1. To assess PD-1 receptor occupancy of GLS-010; 2. To assess the relationship between the expression of PD-L1/PD-L2 and efficacy; 3. To further assess the immunogenicity of GLS-010.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 400 participants
Intervention Model: Sequential Assignment
Intervention Model Description: 1 mg per kg, Q2W; 4 mg per kg, Q2W; 10 mg per kg, Q2W; 240 mg fixed dose, Q2W
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant Human Anti-PD-1 Monoclonal Antibody for Subjects With Advanced Solid Tumors
Actual Study Start Date : July 1, 2017
Estimated Primary Completion Date : July 1, 2020
Estimated Study Completion Date : December 31, 2020

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: GLS-010
Use Full-human anti-pd-1 monoclonal antibodies for treatment
Drug: GLS-010
Recombinant Human Anti-PD-1 Monoclonal Antibody
Other Name: Recombinant Human Anti-PD-1 Monoclonal Antibody




Primary Outcome Measures :
  1. Safety and tolerability of GLS-010 by assessing the percentage of participants who experience a dose-limiting toxicity (DLT) [ Time Frame: 28 days after patient enrolled ]
    To investigate the safety and tolerance profile tolerance profile and the preliminary anti-tumor activity of GLS-010 in subjects with advanced solid tumors ( gastric cancer, esophageal cancer)


Secondary Outcome Measures :
  1. Dose Escalation: Area under the plasma concentration time curve (AUC) of GLS-010 [ Time Frame: within 2 years after patient enrolled ]
    To characterize the pharmacokinetics(PK) profile of GLS-010

  2. severity, seriousness, and relatedness of adverse events [ Time Frame: within 2 years of last patient enrolled ]
    Descriptive statistics will be used to summarize results

  3. Dose Escalation: Maximum concentration (Cmax) of GLS-010 [ Time Frame: within 2 years after patient enrolled ]
    To characterize the pharmacokinetics(PK) profile of GLS-010

  4. Dose Escalation: Half life Period (t1/2) of GLS-010 [ Time Frame: within 2 years after patient enrolled ]
    To characterize the Ppharmacokinetics(K) profile of GLS-010


Other Outcome Measures:
  1. The percent of PD-1 receptor occupancy [ Time Frame: within 2 years of last patient enrolled ]
    To assess PD-1 receptor occupancy of GLS-010



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Willingness to participate in the clinical trial. Provide written informed consent prior to any study-specific screening procedures. Willingness and capability to comply with the requirements of the study;
  • Male or female, Age between 18 and 75 years old (margin included) on the day of signing informed consent.
  • Imaging and histologically/cytologically confirmed diagnosis of advanced solid tumor;Dose escalation study: Subjects with advanced solid tumor (mainly gastric cancer, esophageal cancer)Expansion study: It is estimated that subjects with gastric cancer and esophageal cancer are to be enrolled. The specific cancer type is to be identified later regarding the dose escalation study result.
  • Paraffin embedding sample or biopsy sample available during screening, or be willing to provide tissue from a newly obtained core or excisional biopsy.
  • Have no effective standard treatment or are not respond to standard treatment.
  • Must have at least one measurable lesion as defined per RECIST Version 1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Has a predicted survival period ≥ 12 weeks.
  • Demonstrate adequate organ and hematopoietic function as defined below. a) Hemoglobin (HGB)≥90 g/L;b)White blood cell count (WBC) ≥3×109/L;c)Absolute neutrophil count (ANC) ≥1.5×109/L;d)Platelets ≥100×109/L;e) Serum total bilirubin (TBIL) ≤ 1.5 X upper limit of normal ULN;f) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 X ULN or ≤5 X ULN for subjects with liver metastases;g)Serum creatinine ≤1.5 X ULN;h)International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 X ULN.
  • Since signing the ICF, female or male subjects of childbearing potential should be willing to use an adequate method of contraception with the spouse for the course of the study through 5 months after the last dose of study medication

Exclusion Criteria:

  • Subjects with meningeal or symptomatic central nervous system metastases.
  • Patients with any autoimmune disease, i.e., but not limited to, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (hypothyroidism without clinical symptoms or caused by radiotherapy and chemotherapy can be included); Patients with vitiligo or asthma CR in Childhood, not requiring any intervention in adulthood are permitted to enroll.; patients with asthma requiring a bronchiectasis intervention are not permitted to enroll.
  • Subjects who require systemic corticosteroids (at doses equivalent to or greater than 10 mg/day of prednisone) or other immunosuppressive drugs within 14 days prior to or during the study.
  • Subjects who have received anti-tumor vaccine or who have received anti-tumor drug treatment with immune-stimulating effect within 4 weeks prior to screening.
  • Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137 or anti CTLA-4 antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
  • Presence of other active cancers within 5 years prior to enrollment. Patients with cervical carcinoma in situ/ cured skin basal cell carcinoma who have received definitive adequate treatment are eligible.
  • Participants with active viral hepatitis (positive HepB sAg and/or positive HepB core Ab with positive HepB DNA>103 copies/mL, or positive HepC antibody), or syphilis positive.
  • Subjects with a history of infection with human immunodeficiency virus, or other acquired, congenital immunodeficiency disease, or organ transplantation.
  • Subjects with active tuberculosis infection or active tuberculosis infection within 1 year prior to administration, or subjects with active tuberculosis infection more than 1 year prior to administration without formal treatment.
  • Subjects with active infection or unexplained fever >38.5℃ during screening and prior to first administration (subject with fever caused by tumor may be included in the group as determined by the investigator).
  • History of allergic reactions attributed to any macromolecular protein preparation/monoclonal antibody, or any other composition of the study drug.
  • Investigational drug therapy outside of this trial during or within 4 weeks prior to administration.
  • Has had prior chemotherapy, radiation therapy, targeted small molecule therapy or major surgery within 2 weeks prior to administration; who has not recovered (i.e. ≤ Grade 1 or at baseline) from adverse events due to a previously administered agent (alopecia excluded)
  • Poorly controlled heart disease, such as uncontrolled hyper hypertension, unstable angina pectoris, myocardial infarction within 6 months prior to screening, arrhythmias(including male QTc intervals≥ 450 ms, female QTc intervals≥ 470 ms, QTc intervals calculated by Formula Fridericia).
  • Has history of Interstitial Lung Disease or non-infectious pneumonitis. (Patients caused by radiotherapy are eligible)
  • Has history of alcoholism or drug abuse within 1 year.
  • Has clear history of neurological or mental disorders, i.e. epilepsy, dementia, and poor compliance.
  • Other conditions that do not permit compliance with the protocol, evaluated by the investigator.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03713905


Contacts
Layout table for location contacts
Contact: Lin Shen, MM 8610-88196340 doctorshenlin@sina.cn

Locations
Layout table for location information
China, Beijing
Peking University Cancer Hospital & Institute Recruiting
Beijing, Beijing, China
Contact: Lin Shen, MM    8610-88196340    lin100@medmail.com.cn   
Sponsors and Collaborators
Guangzhou Gloria Biosciences Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Lin Shen, MM Peking University Cancer Hospital & Institute

Layout table for additonal information
Responsible Party: Guangzhou Gloria Biosciences Co., Ltd.
ClinicalTrials.gov Identifier: NCT03713905     History of Changes
Other Study ID Numbers: YH-S001-01
First Posted: October 22, 2018    Key Record Dates
Last Update Posted: October 23, 2018
Last Verified: September 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Antibodies
Immunoglobulins
Antibodies, Monoclonal
Antineoplastic Agents, Immunological
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents